Cartherics granted first US patent for multiple development candidates
Posted: 7 October Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, announced that it has been granted US patent 11,400,145, entitled “Genetically modified cells and uses thereof”. This patent provides a proprietary position…
Refer a student for this special rate
Posted: 7 October Help a university student you know accelerate their studies with essential insight from Australia’s leading business newsroom for $5 per week. What’s included? Unlimited afr.com website access Financial Review iPhone and iPad app Curated daily…
Future You is live!
Future You, an initiative from the Australian Government’s Women in STEM Ambassador, Professor Lisa Harvey-Smith, has launched its Pathfinders series to help children aged 8 to 12 understand and explore pathways to exciting and rewarding STEM careers. The…
Immutep Receives FDA Fast Track Designation for Efti for First Line Non-Small Cell Lung Cancer
Posted: 5 October Fast Track designation has been granted by the US FDA for efti in combination with pembrolizumab in 1st line non-small cell lung cancer • Based on the encouraging Phase II clinical data for PD-L1 all-comers…
Optiscan Featured in Health Leader TV 2022
Posted: 4 October Part of the Australasian College of Health Service Management (ACHSM), Health Leader TV is a leading and trusted source of health service management information across the Australasian region. They provide best practice information, cutting-edge research…
Aculeus Therapeutics announces IND-enabling studies to advance lead program ACU-0943 towards clinical trials
Posted: 3 October Aculeus Therapeutics is a life sciences company focused on discovering and developing novel immunotherapies to treat a range of serious diseases. Today, Aculeus announced that it has initiated Investigational New Drug, or IND-enabling, studies for…
New $2.5m genomics project boosts precision medicine
Posted: 27 September The funding from the Medical Research Future Fund (MRFF) Genomics Health Futures Mission will support research to harness the full potential of genomic data to improve diagnosis and inform clinical care for all patients who…
Cartherics-led Consortium Receives $5.4M Federal Funding for Cellular Immunotherapy Research into Ovarian and Gastric Cancers
Posted: 27 September Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, together within partner institutions, has received $5.4M Medical Research Futures Fund (MRFF) grant to develop a new approach to enhance cancer therapy…
Immutep Receives A$2.7 million R&D Tax Incentive from French Government
Posted: 26 September Immutep Limited, a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a A$2,693,046 research and development (R&D) tax incentive payment in cash from…
$39 million for research partnerships to improve delivery of healthcare
Posted: 26 September The Partnership Projects Scheme provided $14 million from NHMRC and attracted more than $25 million in additional funding from more than 60 partners, with a total of $39 million invested in collaboration between researchers, policy makers…
4DMedical formalises relationship with the University of Melbourne
Posted: 14 September The longstanding relationship between 4DMedcial and its primary research and academic partner, the University of Melbourne, has been formalised through signing of a Memorandum of Understanding (MoU). The two organisations collaborate in a number of…
New Alzheimer’s disease research launches at the Bionics Institute
Posted: 14 September Bionics Institute welcomes Professor Kate Hoy and her team to lead research into a new treatment for Alzheimer’s disease, the most common form of dementia. Professor Hoy joins us from Monash University where she was…
